Granulomatosis with Polyangiitis (Wegener's Granulomatosis): Evolving Concepts in Treatment

Joseph P. Lynch III; Ariis Derhovanessian; Henry Tazelaar; John A. Belperio

doi:10.1055/s-0038-1660874

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2018; 39(04): 434-458
DOI: 10.1055/s-0038-1660874

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Granulomatosis with Polyangiitis (Wegener's Granulomatosis): Evolving Concepts in Treatment

Joseph P. Lynch III

¹Division of Pulmonary, Critical Care Medicine, Allergy and Clinical Immunology, Department of Medicine, The David Geffen School of Medicine at UCLA, Los Angeles, California

,

Ariis Derhovanessian

¹Division of Pulmonary, Critical Care Medicine, Allergy and Clinical Immunology, Department of Medicine, The David Geffen School of Medicine at UCLA, Los Angeles, California

,

Henry Tazelaar

²Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, Arizona

,

John A. Belperio

¹Division of Pulmonary, Critical Care Medicine, Allergy and Clinical Immunology, Department of Medicine, The David Geffen School of Medicine at UCLA, Los Angeles, California

› Author Affiliations

Abstract

Granulomatosis with polyangiitis (GPA), formerly termed Wegener's granulomatosis, is the most common of the pulmonary vasculitides. GPA typically involves the upper respiratory tract, lower respiratory tract (bronchi and lung), and kidney, with varying degrees of disseminated vasculitis. Cardinal histologic features include a necrotizing vasculitis involving small vessels, extensive “geographic” necrosis, and granulomatous inflammation. The spectrum and severity of the disease is heterogeneous, ranging from indolent disease involving only one site to fulminant, multiorgan vasculitis. Circulating antibodies against cytoplasmic components of neutrophils (ANCAs) play a role in the pathogenesis, and often correlate with activity of the disease. Treatment strategies are evolving. Cyclophosphamide (CYC) plus corticosteroids was the mainstay of therapy for generalized, multisystemic GPA since the 1970s. However, within the past decade, rituximab (RTX), a monoclonal antibody directed against B cells, has been shown to be at least as effective (and possibly more effective) as CYC. Furthermore, the use of RTX may reduce the need for maintenance immunosuppression. Optimal therapy for GPA remains controversial, and additional studies are required to determine the role and duration of maintenance therapy following successful induction therapy.

Keywords

granulomatosis with polyangiitis - Wegener's granulomatosis - granulomatous vasculitis - pulmonary vasculitis - capillaritis - antineutrophil cytoplasmic antibodies - rituximab

Full Text

References

References
1 Lynch III JP, Tazelaar H. Wegener granulomatosis (granulomatosis with polyangiitis): evolving concepts in treatment. Semin Respir Crit Care Med 2011; 32 (03) 274-297
2 Lynch III JP, White E, Tazelaar H, Langford CA. Wegener's granulomatosis: evolving concepts in treatment. Semin Respir Crit Care Med 2004; 25 (05) 491-521
3 Singer O, McCune WJ. Update on maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. Curr Opin Rheumatol 2017; 29 (03) 248-253
4 Groh M, Pagnoux C, Baldini C. , et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med 2015; 26 (07) 545-553
5 Binda V, Moroni G, Messa P. ANCA-associated vasculitis with renal involvement. J Nephrol 2018; 31 (02) 197-208
6 Hoffman GS, Kerr GS, Leavitt RY. , et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116 (06) 488-498
7 Reinhold-Keller E, Beuge N, Latza U. , et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43 (05) 1021-1032
8 Abdou NI, Kullman GJ, Hoffman GS. , et al. Wegener's granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. J Rheumatol 2002; 29 (02) 309-316
9 Travis WD. Pathology of pulmonary vasculitis. Semin Respir Crit Care Med 2004; 25 (05) 475-482
10 Watts RA, Gonzales-Gay MA, Garcia-Porrua C, Lane SE, Bentham G, Scott DG. Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe. Ann Rheum Dis 2001; 60 (02) 170-172
11 Watts RA, Lane SE, Bentham G, Scott DG. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum 2000; 43 (02) 414-419
12 Koldingsnes W, Nossent H. Epidemiology of Wegener's granulomatosis in northern Norway. Arthritis Rheum 2000; 43 (11) 2481-2487
13 Pearce FA, Grainge MJ, Lanyon PC, Watts RA, Hubbard RB. The incidence, prevalence and mortality of granulomatosis with polyangiitis in the UK Clinical Practice Research Datalink. Rheumatology (Oxford) 2017; 56 (04) 589-596
14 Mahr A, Guillevin L, Poissonnet M, Aymé S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 2004; 51 (01) 92-99
15 Cotch MF, Hoffman GS, Yerg DE, Kaufman GI, Targonski P, Kaslow RA. The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum 1996; 39 (01) 87-92
16 Gibson A, Stamp LK, Chapman PT, O'Donnell JL. The epidemiology of Wegener's granulomatosis and microscopic polyangiitis in a Southern Hemisphere region. Rheumatology (Oxford) 2006; 45 (05) 624-628
17 Mohammad AJ, Jacobsson LT, Mahr AD, Sturfelt G, Segelmark M. Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford) 2007; 46 (08) 1329-1337
18 Kim HW, Kim JW, Im CH. , et al. The clinicopathologic characteristics of granulomatosis with polyangiitis (Wegener's): a retrospective study of 45 patients in Korea. Mod Rheumatol 2013; 23 (05) 864-871
19 Yoo J, Kim HJ, Ahn SS. , et al. Clinical and prognostic features of Korean patients with MPO-ANCA, PR3-ANCA and ANCA-negative vasculitis. Clin Exp Rheumatol 2017; 35 (01) (Suppl. 103) 111-118
20 Fujimoto S, Watts RA, Kobayashi S. , et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology (Oxford) 2011; 50 (10) 1916-1920
21 Kawasaki A, Yamashita K, Hirano F. , et al. Association of ETS1 polymorphism with granulomatosis with polyangiitis and proteinase 3-anti-neutrophil cytoplasmic antibody positive vasculitis in a Japanese population. J Hum Genet 2018; 63 (01) 55-62
22 Chen M, Yu F, Zhang Y, Zou WZ, Zhao MH, Wang HY. Characteristics of Chinese patients with Wegener's granulomatosis with anti-myeloperoxidase autoantibodies. Kidney Int 2005; 68 (05) 2225-2229
23 Chang DY, Wu LH, Liu G, Chen M, Kallenberg CG, Zhao MH. Re-evaluation of the histopathologic classification of ANCA-associated glomerulonephritis: a study of 121 patients in a single center. Nephrol Dial Transplant 2012; 27 (06) 2343-2349
24 Stegmayr BG, Gothefors L, Malmer B, Müller Wiefel DE, Nilsson K, Sundelin B. Wegener granulomatosis in children and young adults. A case study of ten patients. Pediatr Nephrol 2000; 14 (03) 208-213
25 Belostotsky VM, Shah V, Dillon MJ. Clinical features in 17 paediatric patients with Wegener granulomatosis. Pediatr Nephrol 2002; 17 (09) 754-761
26 Rottem M, Fauci AS, Hallahan CW. , et al. Wegener granulomatosis in children and adolescents: clinical presentation and outcome. J Pediatr 1993; 122 (01) 26-31
27 Cabral DA, Canter DL, Muscal E. , et al; ARChiVe Investigators Network within the PedVas Initiative. Comparing presenting clinical features in 48 children with microscopic polyangiitis to 183 children who have granulomatosis with polyangiitis (Wegener's): an ARChiVe cohort study. Arthritis Rheumatol 2016; 68 (10) 2514-2526
28 Grisaru S, Yuen GW, Miettunen PM, Hamiwka LA. Incidence of Wegener's granulomatosis in children. J Rheumatol 2010; 37 (02) 440-442
29 Iudici M, Quartier P, Terrier B, Mouthon L, Guillevin L, Puéchal X. Childhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysis. Orphanet J Rare Dis 2016; 11 (01) 141
30 Plumb LA, Oni L, Marks SD, Tullus K. Paediatric anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: an update on renal management. Pediatr Nephrol 2018; 33 (01) 25-39
31 Calatroni M, Oliva E, Gianfreda D. , et al. ANCA-associated vasculitis in childhood: recent advances. Ital J Pediatr 2017; 43 (01) 46
32 Fowler NM, Beach JM, Krakovitz P, Spalding SJ. Airway manifestations in childhood granulomatosis with polyangiitis (Wegener's). Arthritis Care Res (Hoboken) 2012; 64 (03) 434-440
33 Lee PY, Adil EA, Irace AL. , et al. The presentation and management of granulomatosis with polyangiitis (Wegener's Granulomatosis) in the pediatric airway. Laryngoscope 2017; 127 (01) 233-240
34 Westwell-Roper C, Lubieniecka JM, Brown KL. , et al; for ARChiVe Investigators Network within the PedVas initiative. Clinical practice variation and need for pediatric-specific treatment guidelines among rheumatologists caring for children with ANCA-associated vasculitis: an international clinician survey. Pediatr Rheumatol Online J 2017; 15 (01) 61
35 Gubbels SP, Barkhuizen A, Hwang PH. Head and neck manifestations of Wegener's granulomatosis. Otolaryngol Clin North Am 2003; 36 (04) 685-705
36 Cannady SB, Batra PS, Koening C. , et al. Sinonasal Wegener granulomatosis: a single-institution experience with 120 cases. Laryngoscope 2009; 119 (04) 757-761
37 Langford CA, Hoffman GS. Rare diseases.3: Wegener's granulomatosis. Thorax 1999; 54 (07) 629-637
38 Rasmussen N. Management of the ear, nose, and throat manifestations of Wegener granulomatosis: an otorhinolaryngologist's perspective. Curr Opin Rheumatol 2001; 13 (01) 3-11
39 Ah-See KW, McLaren K, Maran AG. Wegener's granulomatosis presenting as major salivary gland enlargement. J Laryngol Otol 1996; 110 (07) 691-693
40 Bucolo S, Torre V, Montemagno A, Beatrice F. Wegener's granulomatosis presenting with otologic and neurologic symptoms: clinical and pathological correlations. J Oral Pathol Med 2003; 32 (07) 438-440
41 Liu SY, Vlantis AC, Lee WC. Bilateral parotid and submandibular gland enlargement: rare features of Wegener's granulomatosis. J Laryngol Otol 2003; 117 (02) 148-150
42 Lloyd G, Lund VJ, Beale T, Howard D. Rhinologic changes in Wegener's granulomatosis. J Laryngol Otol 2002; 116 (07) 565-569
43 Devaney KO, Travis WD, Hoffman G, Leavitt R, Lebovics R, Fauci AS. Interpretation of head and neck biopsies in Wegener's granulomatosis. A pathologic study of 126 biopsies in 70 patients. Am J Surg Pathol 1990; 14 (06) 555-564
44 Takwoingi YM, Dempster JH. Wegener's granulomatosis: an analysis of 33 patients seen over a 10-year period. Clin Otolaryngol Allied Sci 2003; 28 (03) 187-194
45 Newman NJ, Slamovits TL, Friedland S, Wilson WB. Neuro-ophthalmic manifestations of meningocerebral inflammation from the limited form of Wegener's granulomatosis. Am J Ophthalmol 1995; 120 (05) 613-621
46 Haynes BF, Fishman ML, Fauci AS, Wolff SM. The ocular manifestations of Wegener's granulomatosis. Fifteen years' experience and review of the literature. Am J Med 1977; 63 (01) 131-141
47 Woo TL, Francis IC, Wilcsek GA, Coroneo MT, McNab AA, Sullivan TJ. ; Australasian Orbital and Adnexal Wagener's Study Group. Australasian orbital and adnexal Wegener's granulomatosis. Ophthalmology 2001; 108 (09) 1535-1543
48 Harper SL, Letko E, Samson CM. , et al. Wegener's granulomatosis: the relationship between ocular and systemic disease. J Rheumatol 2001; 28 (05) 1025-1032
49 Tarabishy AB, Schulte M, Papaliodis GN, Hoffman GS. Wegener's granulomatosis: clinical manifestations, differential diagnosis, and management of ocular and systemic disease. Surv Ophthalmol 2010; 55 (05) 429-444
50 Valmaggia C, Neuweiler J. Orbital involvement as the first manifestation in classic Wegener's granulomatosis. Orbit 2001; 20 (03) 231-237
51 Lamprecht P, Reinhold-Keller E, Gross WL, Reuter M. Clinical images: orbital granuloma and subglottic tracheal stenosis in Wegener's granulomatosis. Arthritis Rheum 2000; 43 (07) 1654
52 Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98 (01) 76-85
53 Niskopoulou M, Du Toit N. Optic neuritis as a feature of Wegener's granulomatosis. Eye (Lond) 2002; 16 (03) 320-321
54 Blum M, Andrassy K, Adler D, Hartmann M, Völcker HE. Early experience with intravenous immunoglobulin treatment in Wegener's granulomatosis with ocular involvement. Graefes Arch Clin Exp Ophthalmol 1997; 235 (09) 599-602
55 Wardyn KA, Ycińska K, Matuszkiewicz-Rowińska J, Chipczyńska M. Pseudotumour orbitae as the initial manifestation in Wegener's granulomatosis in a 7-year-old girl. Clin Rheumatol 2003; 22 (06) 472-474
56 Muller K, Lin JH. Orbital granulomatosis with polyangiitis (Wegener granulomatosis): clinical and pathologic findings. Arch Pathol Lab Med 2014; 138 (08) 1110-1114
57 Hardwig PW, Bartley GB, Garrity JA. Surgical management of nasolacrimal duct obstruction in patients with Wegener's granulomatosis. Ophthalmology 1992; 99 (01) 133-139
58 Kalina PH, Lie JT, Campbell RJ, Garrity JA. Diagnostic value and limitations of orbital biopsy in Wegener's granulomatosis. Ophthalmology 1992; 99 (01) 120-124
59 Pakrou N, Selva D, Leibovitch I. Wegener's granulomatosis: ophthalmic manifestations and management. Semin Arthritis Rheum 2006; 35 (05) 284-292
60 Daum TE, Specks U, Colby TV. , et al. Tracheobronchial involvement in Wegener's granulomatosis. Am J Respir Crit Care Med 1995; 151 (2, Pt 1): 522-526
61 Gluth MB, Shinners PA, Kasperbauer JL. Subglottic stenosis associated with Wegener's granulomatosis. Laryngoscope 2003; 113 (08) 1304-1307
62 Langford CA, Sneller MC, Hallahan CW. , et al. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis. Arthritis Rheum 1996; 39 (10) 1754-1760
63 Screaton NJ, Sivasothy P, Flower CD, Lockwood CM. Tracheal involvement in Wegener's granulomatosis: evaluation using spiral CT. Clin Radiol 1998; 53 (11) 809-815
64 Lynch III JP, Quint LE. Tracheobronchial and esophageal manifestations of systemic diseases. In: Cummings CE, ed. Otolaryngology Head and Neck Surgery, 3rd ed. St. Louis: Mosby-Year Book; 1998: 2343-2367
65 Quint LE, Whyte RI, Kazerooni EA. , et al. Stenosis of the central airways: evaluation by using helical CT with multiplanar reconstructions. Radiology 1995; 194 (03) 871-877
66 Henes FO, Laudien M, Linsenhoff L. , et al. Accuracy of magnetic resonance imaging for grading of subglottic stenosis in patients with granulomatosis with polyangiitis: correlation with pulmonary function tests and laryngoscopy. Arthritis Care Res (Hoboken) 2018; 70 (05) 777-784
67 Nouraei SA, Obholzer R, Ind PW. , et al. Results of endoscopic surgery and intralesional steroid therapy for airway compromise due to tracheobronchial Wegener's granulomatosis. Thorax 2008; 63 (01) 49-52
68 Gotway MB, Golden JA, LaBerge JM. , et al. Benign tracheobronchial stenoses: changes in short-term and long-term pulmonary function testing after expandable metallic stent placement. J Comput Assist Tomogr 2002; 26 (04) 564-572
69 Shin MS, Young KR, Ho KJ. Wegener's granulomatosis upper respiratory tract and pulmonary radiographic manifestations in 30 cases with pathogenetic consideration. Clin Imaging 1998; 22 (02) 99-104
70 Komócsi A, Reuter M, Heller M, Muraközi H, Gross WL, Schnabel A. Active disease and residual damage in treated Wegener's granulomatosis: an observational study using pulmonary high-resolution computed tomography. Eur Radiol 2003; 13 (01) 36-42
71 Lynch III JP, Leatherman JW. Alveolar hemorrhage syndromes. In: Fishman A. , ed. Pulmonary Diseases and Disorders, 3rd ed. New York, NY: McGraw-Hill; 1997: 1193-1210
72 Travis WD, Colby TV, Lombard C, Carpenter HA. A clinicopathologic study of 34 cases of diffuse pulmonary hemorrhage with lung biopsy confirmation. Am J Surg Pathol 1990; 14 (12) 1112-1125
73 Lee KS, Kim TS, Fujimoto K. , et al. Thoracic manifestation of Wegener's granulomatosis: CT findings in 30 patients. Eur Radiol 2003; 13 (01) 43-51
74 Reuter M, Schnabel A, Wesner F. , et al. Pulmonary Wegener's granulomatosis: correlation between high-resolution CT findings and clinical scoring of disease activity. Chest 1998; 114 (02) 500-506
75 Sheehan RE, Flint JD, Müller NL. Computed tomography features of the thoracic manifestations of Wegener granulomatosis. J Thorac Imaging 2003; 18 (01) 34-41
76 Nelson DR, Johnson GB, Cartin-Ceba R, Specks U. Characterization of F-18 fluorodeoxyglucose PET/CT in granulomatosis with polyangiitis. Sarcoidosis Vasc Diffuse Lung Dis 2016; 32 (04) 342-352
77 De Geeter F, Gykiere P. (18)F-FDG PET imaging of granulomatosis with polyangiitis -Wegener's Syndrome. Hell J Nucl Med 2016; 19 (01) 53-56
78 Hervier B, Pagnoux C, Agard C. , et al; French Vasculitis Study Group. Pulmonary fibrosis associated with ANCA-positive vasculitides. Retrospective study of 12 cases and review of the literature. Ann Rheum Dis 2009; 68 (03) 404-407
79 Alba MA, Flores-Suárez LF, Henderson AG. , et al. Interstitial lung disease in ANCA vasculitis. Autoimmun Rev 2017; 16 (07) 722-729
80 Comarmond C, Crestani B, Tazi A. , et al. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature. Medicine (Baltimore) 2014; 93 (24) 340-349
81 Fernandez Casares M, Gonzalez A, Fielli M, Caputo F, Bottinelli Y, Zamboni M. Microscopic polyangiitis associated with pulmonary fibrosis. Clin Rheumatol 2015; 34 (07) 1273-1277
82 Homma S, Suzuki A, Sato K. Pulmonary involvement in ANCA-associated vasculitis from the view of the pulmonologist. Clin Exp Nephrol 2013; 17 (05) 667-671
83 Tzelepis GE, Kokosi M, Tzioufas A. , et al. Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis. Eur Respir J 2010; 36 (01) 116-121
84 Travis WD, Hoffman GS, Leavitt RY, Pass HI, Fauci AS. Surgical pathology of the lung in Wegener's granulomatosis. Review of 87 open lung biopsies from 67 patients. Am J Surg Pathol 1991; 15 (04) 315-333
85 Carruthers DM, Connor S, Howie AJ. , et al. Percutaneous image-guided biopsy of lung nodules in the assessment of disease activity in Wegener's granulomatosis. Rheumatology (Oxford) 2000; 39 (07) 776-782
86 Gómez-Puerta JA, Hernández-Rodríguez J, López-Soto A, Bosch X. Antineutrophil cytoplasmic antibody-associated vasculitides and respiratory disease. Chest 2009; 136 (04) 1101-1111
87 Casian A, Jayne D. Management of alveolar hemorrhage in lung vasculitides. Semin Respir Crit Care Med 2011; 32 (03) 335-345
88 Krause ML, Cartin-Ceba R, Specks U, Peikert T. Update on diffuse alveolar hemorrhage and pulmonary vasculitis. Immunol Allergy Clin North Am 2012; 32 (04) 587-600
89 Kostianovsky A, Hauser T, Pagnoux C. , et al; French Vasculitis Study Group (FVSG). Alveolar haemorrhage in ANCA-associated vasculitides: 80 patients' features and prognostic factors. Clin Exp Rheumatol 2012; 30 (01) (Suppl. 70) S77-S82
90 Aasarød K, Bostad L, Hammerstrøm J, Jørstad S, Iversen BM. Renal histopathology and clinical course in 94 patients with Wegener's granulomatosis. Nephrol Dial Transplant 2001; 16 (05) 953-960
91 Geetha D, Hruskova Z, Segelmark M. , et al. Rituximab for treatment of severe renal disease in ANCA associated vasculitis. J Nephrol 2016; 29 (02) 195-201
92 Bajema IM, Hagen EC, Hermans J. , et al. Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. Kidney Int 1999; 56 (05) 1751-1758
93 Mekhail TM, Hoffman GS. Long-term outcome of Wegener's granulomatosis in patients with renal disease requiring dialysis. J Rheumatol 2000; 27 (05) 1237-1240
94 Haubitz M, Koch KM, Brunkhorst R. Survival and vasculitis activity in patients with end-stage renal disease due to Wegener's granulomatosis. Nephrol Dial Transplant 1998; 13 (07) 1713-1718
95 Gottenberg JE, Mahr A, Pagnoux C, Cohen P, Mouthon L, Guillevin L. ; French Vasculitis Study Group (FVSG). Long-term outcome of 37 patients with Wegener's granulomatosis with renal involvement. Presse Med 2007; 36 (5, Pt 1): 771-778
96 Jayne DR, Gaskin G, Rasmussen N. , et al; European Vasculitis Study Group. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18 (07) 2180-2188
97 Walsh M, Casian A, Flossmann O. , et al; European Vasculitis Study Group (EUVAS). Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int 2013; 84 (02) 397-402
98 Malina M, Schaefer B, Waldherr R, Wühl E, Schaefer F, Schmitt CP. Late recovery of renal function by rituximab in a patient with Wegener's granulomatosis. Pediatr Nephrol 2013; 28 (03) 511-514
99 Szpirt WM, Heaf JG, Petersen J. Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis--a clinical randomized controlled trial. Nephrol Dial Transplant 2011; 26 (01) 206-213
100 Walsh M, Merkel PA, Peh CA. , et al; PEXIVAS Investigators. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials 2013; 14: 73
101 Aasarød K, Iversen BM, Hammerstrøm J, Bostad L, Vatten L, Jørstad S. Wegener's granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant 2000; 15 (05) 611-618
102 Hruskova Z, Geetha D, Tesar V. Renal transplantation in anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrol Dial Transplant 2015; 30 (Suppl. 01) i159-i163
103 Noone D, Yeung RSM, Hebert D. Outcome of kidney transplantation in pediatric patients with ANCA-associated glomerulonephritis: a single-center experience. Pediatr Nephrol 2017; 32 (12) 2343-2350
104 Göçeroğlu A, Rahmattulla C, Berden AE. , et al. The Dutch Transplantation in Vasculitis (DUTRAVAS) Study: outcome of renal transplantation in antineutrophil cytoplasmic antibody-associated glomerulonephritis. Transplantation 2016; 100 (04) 916-924
105 Shen J, Gill J, Shangguan M, Sampaio MS, Bunnapradist S. Outcomes of renal transplantation in recipients with Wegener's granulomatosis. Clin Transplant 2011; 25 (03) 380-387
106 Little MA, Hassan B, Jacques S. , et al. Renal transplantation in systemic vasculitis: when is it safe?. Nephrol Dial Transplant 2009; 24 (10) 3219-3225
107 Gera M, Griffin MD, Specks U, Leung N, Stegall MD, Fervenza FC. Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosuppression. Kidney Int 2007; 71 (12) 1296-1301
108 Nachman PH, Segelmark M, Westman K. , et al. Recurrent ANCA-associated small vessel vasculitis after transplantation: a pooled analysis. Kidney Int 1999; 56 (04) 1544-1550
109 Marco H, Mirapeix E, Arcos E. , et al; Catalan Study Group of Glomerular Diseases (GLOMCAT). Long-term outcome of antineutrophil cytoplasmic antibody-associated small vessel vasculitis after renal transplantation. Clin Transplant 2013; 27 (03) 338-347
110 Hensle TW, Mitchell ME, Crooks KK, Robinson D. Urologic manifestations of Wegener granulomatosis. Urology 1978; 12 (05) 553-556
111 Dufour JF, Le Gallou T, Cordier JF. , et al; French Center-East Internists Group; French Vasculitis Study Group. Urogenital manifestations in Wegener granulomatosis: a study of 11 cases and review of the literature. Medicine (Baltimore) 2012; 91 (02) 67-74
112 Umemoto A, Ikeuchi H, Hiromura K. , et al. Hydronephrosis caused by a relapse of granulomatosis with polyangiitis (Wegener's). Mod Rheumatol 2012; 22 (04) 616-620
113 Baker SB, Robinson DR. Unusual renal manifestations of Wegener's granulomatosis. Report of two cases. Am J Med 1978; 64 (05) 883-889
114 Huong DL, Papo T, Piette JC. , et al. Urogenital manifestations of Wegener granulomatosis. Medicine (Baltimore) 1995; 74 (03) 152-161
115 Frigui M, Ben Hmida M, Kechaou M, Jlidi R, Bahloul Z. Wegener's granulomatosis presenting as multiple bilateral renal masses: case report and literature review. Rheumatol Int 2009; 29 (06) 679-683
116 Gunnarsson R, Omdal R, Kjellevold KH, Ellingsen CL. Wegener's granulomatosis of the prostate gland. Rheumatol Int 2004; 24 (02) 120-122
117 Thompson G, Klecka M, Roden AC, Specks U, Cartin-Ceba R. Biopsy-proven pulmonary capillaritis: a retrospective study of aetiologies including an in-depth look at isolated pulmonary capillaritis. Respirology 2016; 21 (04) 734-738
118 Quadrelli S, Dubinsky D, Solis M. , et al. Immune diffuse alveolar hemorrhage: Clinical presentation and outcome. Respir Med 2017; 129: 59-62
119 Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC, Falk RJ. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 2003; 42 (06) 1149-1153
120 Cartin-Ceba R, Diaz-Caballero L, Al-Qadi MO. , et al. Diffuse alveolar hemorrhage secondary to antineutrophil cytoplasmic antibody-associated vasculitis: predictors of respiratory failure and clinical outcomes. Arthritis Rheumatol 2016; 68 (06) 1467-1476
121 Nishino H, Rubino FA, DeRemee RA, Swanson JW, Parisi JE. Neurological involvement in Wegener's granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol 1993; 33 (01) 4-9
122 de Groot K, Schmidt DK, Arlt AC, Gross WL, Reinhold-Keller E. Standardized neurologic evaluations of 128 patients with Wegener granulomatosis. Arch Neurol 2001; 58 (08) 1215-1221
123 Graf J. Central nervous system disease in antineutrophil cytoplasmic antibodies-associated vasculitis. Rheum Dis Clin North Am 2017; 43 (04) 573-578
124 Holle JU, Gross WL. Neurological involvement in Wegener's granulomatosis. Curr Opin Rheumatol 2011; 23 (01) 7-11
125 Weinberger LM, Cohen ML, Remler BF, Naheedy MH, Leigh RJ. Intracranial Wegener's granulomatosis. Neurology 1993; 43 (09) 1831-1834
126 Garovic VD, Clarke BL, Chilson TS, Specks U. Diabetes insipidus and anterior pituitary insufficiency as presenting features of Wegener's granulomatosis. Am J Kidney Dis 2001; 37 (01) E5
127 Woywodt A, Knoblauch H, Kettritz R, Schneider W, Göbel U. Sudden death and Wegener's granulomatosis of the pituitary. Scand J Rheumatol 2000; 29 (04) 264-266
128 De Parisot A, Puéchal X, Langrand C. , et al; French Vasculitis Study Group. Pituitary involvement in granulomatosis with polyangiitis: report of 9 patients and review of the literature. Medicine (Baltimore) 2015; 94 (16) e748
129 Esposito D, Trimpou P, Giugliano D, Dehlin M, Ragnarsson O. Pituitary dysfunction in granulomatosis with polyangiitis. Pituitary 2017; 20 (05) 594-601
130 Mattioli F, Capra R, Rovaris M. , et al. Frequency and patterns of subclinical cognitive impairment in patients with ANCA-associated small vessel vasculitides. J Neurol Sci 2002; 195 (02) 161-166
131 Murphy JM, Gomez-Anson B, Gillard JH. , et al. Wegener granulomatosis: MR imaging findings in brain and meninges. Radiology 1999; 213 (03) 794-799
132 Higuera-Ortiz V, Reynoso A, Ruiz N, Delgado-Hernández RD, Gómez-Garza G, Flores-Suárez LF. Pachymeningitis in granulomatosis with polyangiitis: case series with earlier onset in younger patients and literature review. Clin Rheumatol 2017; 36 (04) 919-924
133 Mentzel HJ, Neumann T, Fitzek C, Sauner D, Reichenbach JR, Kaiser WA. MR Imaging in Wegener granulomatosis of the spinal cord. AJNR Am J Neuroradiol 2003; 24 (01) 18-21
134 Comfere NI, Macaron NC, Gibson LE. Cutaneous manifestations of Wegener's granulomatosis: a clinicopathologic study of 17 patients and correlation to antineutrophil cytoplasmic antibody status. J Cutan Pathol 2007; 34 (10) 739-747
135 Barksdale SK, Hallahan CW, Kerr GS, Fauci AS, Stern JB, Travis WD. Cutaneous pathology in Wegener's granulomatosis. A clinicopathologic study of 75 biopsies in 46 patients. Am J Surg Pathol 1995; 19 (02) 161-172
136 Morelli S, Gurgo Di Castelmenardo AM, Conti F. , et al. Cardiac involvement in patients with Wegener's granulomatosis. Rheumatol Int 2000; 19 (06) 209-212
137 McGeoch L, Carette S, Cuthbertson D. , et al; Vasculitis Clinical Research Consortium. Cardiac involvement in granulomatosis with polyangiitis. J Rheumatol 2015; 42 (07) 1209-1212
138 Kouba DJ, Kirsch DG, Mimouni D, Nousari CH. Wegener's granulomatosis with cardiac involvement masquerading as Lyme disease. Clin Exp Rheumatol 2003; 21 (05) 647-649
139 Kyaw H, Misra D, Mani MM, Park WJ, Shinnar M. Unusual cardiac involvement in granulomatosis with polyangiitis manifesting as acute congestive heart failure. Anatol J Cardiol 2017; 18 (02) 158-160
140 Parry SD, Clark DM, Campbell J. Coronary arteritis in Wegener's granulomatosis causing fatal myocardial infarction. Hosp Med 2000; 61 (04) 284-285
141 Hazebroek MR, Kemna MJ, Schalla S. , et al. Prevalence and prognostic relevance of cardiac involvement in ANCA-associated vasculitis: eosinophilic granulomatosis with polyangiitis and granulomatosis with polyangiitis. Int J Cardiol 2015; 199: 170-179
142 Kemna MJ, Vandergheynst F, Vöö S. , et al. Positron emission tomography scanning in anti-neutrophil cytoplasmic antibodies-associated vasculitis. Medicine (Baltimore) 2015; 94 (20) e747
143 Schmidt WA, Seipelt E, Molsen HP, Poehls C, Gromnica-ihle EJ. Vasculitis of the internal carotid artery in Wegener's granulomatosis: comparison of ultrasonography, angiography, and MRI. Scand J Rheumatol 2001; 30 (01) 48-50
144 Blockmans D, Baeyens H, Van Loon R, Lauwers G, Bobbaers H. Periaortitis and aortic dissection due to Wegener's granulomatosis. Clin Rheumatol 2000; 19 (02) 161-164
145 Kemna MJ, Bucerius J, Drent M. , et al. Aortic ¹⁸F-FDG uptake in patients suffering from granulomatosis with polyangiitis. Eur J Nucl Med Mol Imaging 2015; 42 (09) 1423-1429
146 Chang YJ, Kerr LD. Isolated abdominal vasculitis as an atypical presentation of Wegener's granulomatosis. Am J Gastroenterol 2000; 95 (01) 297-298
147 Haworth SJ, Pusey CD. Severe intestinal involvement in Wegener's granulomatosis. Gut 1984; 25 (11) 1296-1300
148 Camilleri M, Pusey CD, Chadwick VS, Rees AJ. Gastrointestinal manifestations of systemic vasculitis. Q J Med 1983; 52 (206) 141-149
149 Steele C, Bohra S, Broe P, Murray FE. Acute upper gastrointestinal haemorrhage and colitis: an unusual presentation of Wegener's granulomatosis. Eur J Gastroenterol Hepatol 2001; 13 (08) 993-995
150 Sokol RJ, Farrell MK, McAdams AJ. An unusual presentation of Wegener's granulomatosis mimicking inflammatory bowel disease. Gastroenterology 1984; 87 (02) 426-432
151 Qian Q, Cornell L, Chandan V, Hartman R, Caples S. Hemorrhagic colitis as a presenting feature of Wegener granulomatosis. J Gastrointestin Liver Dis 2010; 19 (04) 445-447
152 Zheng Z, Ding J, Li X, Wu Z. Gastric presentation (vasculitis) mimics a gastric cancer as initial symptom in granulomatosis with polyangiitis: a case report and review of the literature. Rheumatol Int 2015; 35 (11) 1925-1929
153 Zen Y, Sunagozaka H, Tsuneyama K. , et al. Incomplete septal cirrhosis associated with Wegener's granulomatosis. Liver 2002; 22 (05) 388-393
154 Holl-Ulrich K, Klass M. Wegener s granulomatosis with granulomatous liver involvement. Clin Exp Rheumatol 2010; 28 (01) (Suppl. 57) 88-89
155 Rentsch J, McColl G. Splenic infarction in Wegener's granulomatosis. J Rheumatol 2000; 27 (06) 1554-1555
156 Kalaitzoglou I, Drevelengas A, Palladas P, Asimaki A. MRI appearance of pulmonary Wegener's granulomatosis with concomitant splenic infarction. Eur Radiol 1998; 8 (03) 367-370
157 Ramirez GA, Della-Torre E, Campochiaro C. , et al. Juxta-vertebral lesions in granulomatosis with polyangiitis. Semin Arthritis Rheum 2016; 46 (03) 356-360
158 Della-Torre E, Lanzillotta M, Campochiaro C. , et al. Antineutrophil cytoplasmic antibody positivity in IgG4-related disease: a case report and review of the literature. Medicine (Baltimore) 2016; 95 (34) e4633
159 Danlos FX, Rossi GM, Blockmans D. , et al; French Vasculitis Study Group. Antineutrophil cytoplasmic antibody-associated vasculitides and IgG4-related disease: a new overlap syndrome. Autoimmun Rev 2017; 16 (10) 1036-1043
160 Fishbein GA, Fishbein MC. Lung vasculitis and alveolar hemorrhage: pathology. Semin Respir Crit Care Med 2011; 32 (03) 254-263
161 Kallenberg CG. Antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Curr Opin Rheumatol 2007; 19 (01) 17-24
162 Kallenberg CG. Pathogenesis of PR3-ANCA associated vasculitis. J Autoimmun 2008; 30 (1-2): 29-36
163 Bossuyt X, Cohen Tervaert JW, Arimura Y. , et al. Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol 2017; 13 (11) 683-692
164 Miloslavsky EM, Lu N, Unizony S. , et al. Myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA)-positive and ANCA-negative patients with granulomatosis with polyangiitis (Wegener's): distinct patient subsets. Arthritis Rheumatol 2016; 68 (12) 2945-2952
165 Boomsma MM, Stegeman CA, van der Leij MJ. , et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000; 43 (09) 2025-2033
166 Thai LH, Charles P, Resche-Rigon M, Desseaux K, Guillevin L. Are anti-proteinase-3 ANCA a useful marker of granulomatosis with polyangiitis (Wegener's) relapses? Results of a retrospective study on 126 patients. Autoimmun Rev 2014; 13 (03) 313-318
167 Langford CA. The diagnostic utility of c-ANCA in Wegener's granulomatosis. Cleve Clin J Med 1998; 65 (03) 135-140
168 Morgan MD, Szeto M, Walsh M. , et al; European Vasculitis Society. Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse. Arthritis Res Ther 2017; 19 (01) 129
169 Solans-Laqué R, Fraile G, Rodriguez-Carballeira M. , et al; Spanish Registry of systemic vasculitis (REVAS) from the Autoimmune Diseases Study Group (GEAS) of the Spanish Society of Internal Medicine (SEMI). Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides: impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity. Medicine (Baltimore) 2017; 96 (08) e6083
170 Schirmer JH, Wright MN, Herrmann K. , et al. Myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA)-positive granulomatosis with polyangiitis (Wegener's) is a clinically distinct subset of ANCA-associated vasculitis: a retrospective analysis of 315 patients from a German vasculitis referral center. Arthritis Rheumatol 2016; 68 (12) 2953-2963
171 Mohammad AJ, Mortensen KH, Babar J. , et al. Pulmonary involvement in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: the influence of ANCA subtype. J Rheumatol 2017; 44 (10) 1458-1467
172 Xiao H, Hu P, Falk RJ, Jennette JC. Overview of the pathogenesis of ANCA-associated vasculitis. Kidney Dis (Basel) 2016; 1 (04) 205-215
173 Jennette JC, Falk RJ. B cell-mediated pathogenesis of ANCA-mediated vasculitis. Semin Immunopathol 2014; 36 (03) 327-338
174 Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol 2014; 10 (08) 463-473
175 Merkel PA, Xie G, Monach PA. , et al; Vasculitis Clinical Research Consortium. Identification of functional and expression polymorphisms associated with risk for antineutrophil cytoplasmic autoantibody-associated vasculitis. Arthritis Rheumatol 2017; 69 (05) 1054-1066
176 Lyons PA, Rayner TF, Trivedi S. , et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012; 367 (03) 214-223
177 Xie G, Roshandel D, Sherva R. , et al. Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. Arthritis Rheum 2013; 65 (09) 2457-2468
178 Cartin-Ceba R, Indrakanti D, Specks U. , et al; RAVE-Immune Tolerance Network Research Group. The pharmacogenomic association of Fcγ receptors and cytochrome P450 enzymes with response to rituximab or cyclophosphamide treatment in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 2017; 69 (01) 169-175
179 Exley AR, Bacon PA, Luqmani RA, Kitas GD, Carruthers DM, Moots R. Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI). Br J Rheumatol 1998; 37 (01) 57-63
180 Stone JH, Hoffman GS, Merkel PA. , et al; International Network for the Study of the Systemic Vasculitides (INSSYS). A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. Arthritis Rheum 2001; 44 (04) 912-920
181 Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). BMJ 1958; 2 (5091): 265-270
182 Hoffman GS. “Wegener's granulomatosis”: the path traveled since 1931. Medicine (Baltimore) 1994; 73 (06) 325-329
183 Hollander D, Manning RT. The use of alkylating agents in the treatment of Wegener's granulomatosis. Ann Intern Med 1967; 67 (02) 393-398
184 Fauci AS, Wolff SM. Wegener's granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore) 1973; 52 (06) 535-561
185 Reinhold-Keller E, Kekow J, Schnabel A. , et al. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum 1994; 37 (06) 919-924
186 Guillevin L, Cordier JF, Lhote F. , et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997; 40 (12) 2187-2198
187 Charlier C, Henegar C, Launay O. , et al. Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis 2009; 68 (05) 658-663
188 Talar-Williams C, Hijazi YM, Walther MM. , et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996; 124 (05) 477-484
189 Faurschou M, Sorensen IJ, Mellemkjaer L. , et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008; 35 (01) 100-105
190 Mohammad AJ, Segelmark M, Smith R. , et al. Severe infection in antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol 2017; 44 (10) 1468-1475
191 Robson J, Doll H, Suppiah R. , et al. Damage in the ANCA-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis 2015; 74 (01) 177-184
192 Hruskova Z, Stel VS, Jayne D. , et al. Characteristics and outcomes of granulomatosis with polyangiitis (Wegener) and microscopic polyangiitis requiring renal replacement therapy: results from the European Renal Association-European Dialysis and Transplant Association Registry. Am J Kidney Dis 2015; 66 (04) 613-620
193 Cornec D, Cornec-Le Gall E, Specks U. Clinical trials in antineutrophil cytoplasmic antibody-associated vasculitis: what we have learnt so far, and what we still have to learn. Nephrol Dial Transplant 2017; 32 (Suppl. 01) i37-i47
194 Jayne D, Rasmussen N, Andrassy K. , et al; European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349 (01) 36-44
195 Pagnoux C, Mahr A, Hamidou MA. , et al; French Vasculitis Study Group. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008; 359 (26) 2790-2803
196 Hoffman GS, Leavitt RY, Fleisher TA, Minor JR, Fauci AS. Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med 1990; 89 (04) 403-410
197 de Groot K, Harper L, Jayne DR. , et al; EUVAS (European Vasculitis Study Group). Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150 (10) 670-680
198 Pagnoux C, Quéméneur T, Ninet J. , et al; French Vasculitis Study Group. Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol 2015; 67 (04) 1117-1127
199 Seror R, Pagnoux C, Ruivard M. , et al; French Vasculitis Study Group. Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial. Ann Rheum Dis 2010; 69 (12) 2125-2130
200 Sneller MC, Hoffman GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995; 38 (05) 608-613
201 Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 2000; 43 (08) 1836-1840
202 de Groot K, Reinhold-Keller E, Tatsis E. , et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Methotrexate versus trimethoprim/sulfamethoxazole. Arthritis Rheum 1996; 39 (12) 2052-2061
203 Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004; 51 (02) 278-283
204 Jayne D. Leflunomide versus methotrexate in Wegener's granulomatosis. Rheumatology (Oxford) 2007; 46 (07) 1047-1048
205 Jones RB, Tervaert JW, Hauser T. , et al; European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363 (03) 211-220
206 Stone JH, Merkel PA, Spiera R. , et al; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363 (03) 221-232
207 Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. ; Dutch Co-Trimoxazole Wegener Study Group. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N Engl J Med 1996; 335 (01) 16-20
208 Reinhold-Keller E, De Groot K, Rudert H, Nölle B, Heller M, Gross WL. Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. QJM 1996; 89 (01) 15-23
209 Lynch III JP, McCune WJ. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med 1997; 155 (02) 395-420
210 Wang T, Weigt SS, Belperio JA, Lynch III JP. Immunosuppressive and cytotoxic therapy: pharmacology, toxicities, and monitoring. Semin Respir Crit Care Med 2011; 32 (03) 346-370
211 Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999; 42 (12) 2666-2673
212 Bernatsky S, Ramsey-Goldman R, Clarke AE. Malignancies and cyclophosphamide exposure in Wegener's granulomatosis. J Rheumatol 2008; 35 (01) 11-13
213 Stone JH, Holbrook JT, Marriott MA. , et al; Wegener's Granulomatosis Etanercept Trial Research Group. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2006; 54 (05) 1608-1618
214 de Groot K, Adu D, Savage CO. ; EUVAS (European Vasculitis Study Group). The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001; 16 (10) 2018-2027
215 de Groot K, Mühler M, Reinhold-Keller E, Paulsen J, Gross WL. Induction of remission in Wegener's granulomatosis with low dose methotrexate. J Rheumatol 1998; 25 (03) 492-495
216 Stone JH, Tun W, Hellman DB. Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. J Rheumatol 1999; 26 (05) 1134-1139
217 Villa-Forte A, Clark TM, Gomes M. , et al. Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience. Medicine (Baltimore) 2007; 86 (05) 269-277
218 Maritati F, Alberici F, Oliva E. , et al. Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: a randomised trial. PLoS One 2017; 12 (10) e0185880
219 Guillevin L, Pagnoux C, Karras A. , et al; French Vasculitis Study Group. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014; 371 (19) 1771-1780
220 Nowack R, Göbel U, Klooker P, Hergesell O, Andrassy K, van der Woude FJ. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999; 10 (09) 1965-1971
221 Iatrou C, Zerbala S, Revela I. , et al. Mycophenolate mofetil as maintenance therapy in patients with vasculitis and renal involvement. Clin Nephrol 2009; 72 (01) 31-37
222 Joy MS, Hogan SL, Jennette JC, Falk RJ, Nachman PH. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant 2005; 20 (12) 2725-2732
223 Hiemstra TF, Walsh M, Mahr A. , et al; European Vasculitis Study Group (EUVAS). Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010; 304 (21) 2381-2388
224 Bremer JP, Ullrich S, Laudien M, Gross WL, Lamprecht P. Methotrexate plus leflunomide for the treatment of relapsing Wegener's granulomatosis. A retrospective uncontrolled study. Clin Exp Rheumatol 2010; 28 (01) (Suppl. 57) 67-71
225 Metzler C, Miehle N, Manger K. , et al; German Network of Rheumatic Diseases. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) 2007; 46 (07) 1087-1091
226 Metzler C, Fink C, Lamprecht P, Gross WL, Reinhold-Keller E. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxford) 2004; 43 (03) 315-320
227 Israel HL, Patchefsky AS, Saldana MJ. Wegener's granulomatosis, lymphomatoid granulomatosis, and benign lymphocytic angiitis and granulomatosis of lung. Recognition and treatment. Ann Intern Med 1977; 87 (06) 691-699
228 Weiner SR, Paulus HE. Treatment of Wegener's granulomatosis. Semin Respir Med 1989; 10: 156-161
229 Hinze CH, Colbert RA. B-cell depletion in Wegener's granulomatosis. Clin Rev Allergy Immunol 2008; 34 (03) 372-379
230 Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 2006; 45 (11) 1432-1436
231 Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173 (02) 180-187
232 Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52 (01) 262-268
233 Memet B, Rudinskaya A, Krebs T, Oelberg D. Wegener granulomatosis with massive intracerebral hemorrhage: remission of disease in response to rituximab. J Clin Rheumatol 2005; 11 (06) 314-318
234 Tamura N, Matsudaira R, Hirashima M. , et al. Two cases of refractory Wegener's granulomatosis successfully treated with rituximab. Intern Med 2007; 46 (07) 409-414
235 Specks U, Fervenza FC, McDonald TJ, Hogan MC. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001; 44 (12) 2836-2840
236 Brihaye B, Aouba A, Pagnoux C, Cohen P, Lacassin F, Guillevin L. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. Clin Exp Rheumatol 2007; 25 (01) (Suppl. 44) S23-S27
237 Onal S, Kazokoglu H, Koc A, Yavuz S. Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener's granulomatosis. Ocul Immunol Inflamm 2008; 16 (05) 230-232
238 Hermle T, Goestemeyer AK, Sweny P, Burns A. Successful therapeutic use of rituximab in refractory Wegener's granulomatosis after renal transplantation. Clin Nephrol 2007; 68 (05) 322-326
239 Roccatello D, Baldovino S, Alpa M. , et al. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol 2008; 26 (03) (Suppl. 49) S67-S71
240 Jones RB, Ferraro AJ, Chaudhry AN. , et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60 (07) 2156-2168
241 Jones RB, Furuta S, Tervaert JW. , et al; European Vasculitis Society (EUVAS). Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis 2015; 74 (06) 1178-1182
242 Sharma A, Kumar S, Wanchu A. , et al. Successful treatment of hypertrophic pachymeningitis in refractory Wegener's granulomatosis with rituximab. Clin Rheumatol 2010; 29 (01) 107-110
243 Cheung CM, Murray PI, Savage CO. Successful treatment of Wegener's granulomatosis associated scleritis with rituximab. Br J Ophthalmol 2005; 89 (11) 1542
244 Calich AL, Puéchal X, Pugnet G. , et al; French Vasculitis Study Group. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients. J Autoimmun 2014; 50: 135-141
245 Aries PM, Hellmich B, Voswinkel J. , et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006; 65 (07) 853-858
246 Martinez Del Pero M, Chaudhry A, Jones RB, Sivasothy P, Jani P, Jayne D. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. Clin Otolaryngol 2009; 34 (04) 328-335
247 Taylor SR, Salama AD, Joshi L, Pusey CD, Lightman SL. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 2009; 60 (05) 1540-1547
248 Specks U, Merkel PA, Seo P. , et al; RAVE-ITN Research Group. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013; 369 (05) 417-427
249 Alberici F, Smith RM, Jones RB. , et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford) 2015; 54 (07) 1153-1160
250 Roccatello D, Sciascia S, Rossi D. , et al. The “4 plus 2” rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study. Oncotarget 2017; 8 (32) 52072-52077
251 Yates M, Watts RA, Bajema IM. , et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 2016; 75 (09) 1583-1594
252 Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010; 61: 35-47
253 Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 2009; 18 (09) 767-776
254 Roberts DM, Jones RB, Smith RM. , et al. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun 2015; 57: 60-65
255 Bayry J, Negi VS, Kaveri SV. Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol 2011; 7 (06) 349-359
256 Richter C, Schnabel A, Csernok E, De Groot K, Reinhold-Keller E, Gross WL. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 1995; 101 (01) 2-7
257 Ito-Ihara T, Ono T, Nogaki F. , et al. Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis. Nephron Clin Pract 2006; 102 (01) c35-c42
258 Martinez V, Cohen P, Pagnoux C. , et al; French Vasculitis Study Group. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum 2008; 58 (01) 308-317
259 Jayne DR, Chapel H, Adu D. , et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000; 93 (07) 433-439
260 Crickx E, Machelart I, Lazaro E. , et al; French Vasculitis Study Group. Intravenous immunoglobulin as an immunomodulating agent in antineutrophil cytoplasmic antibody-associated vasculitides: a French nationwide study of ninety-two patients. Arthritis Rheumatol 2016; 68 (03) 702-712
261 Lamprecht P, Voswinkel J, Lilienthal T. , et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002; 41 (11) 1303-1307
262 Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 2001; 44 (05) 1149-1154
263 Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352 (04) 351-361
264 Josselin L, Mahr A, Cohen P. , et al. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. Ann Rheum Dis 2008; 67 (09) 1343-1346
265 Bartolucci P, Ramanoelina J, Cohen P. , et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002; 41 (10) 1126-1132
266 Booth AD, Jefferson HJ, Ayliffe W, Andrews PA, Jayne DR. Safety and efficacy of TNFalpha blockade in relapsing vasculitis. Ann Rheum Dis 2002; 61 (06) 559
267 Hermann J, Reittner P, Scarpatetti M, Graninger W. Successful treatment of meningeal involvement in Wegener's granulomatosis with infliximab. Ann Rheum Dis 2006; 65 (05) 691-692
268 Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis 2008; 67 (09) 1322-1327
269 Dick AD, Meyer P, James T. , et al. Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol 2000; 84 (01) 107-109
270 Lockwood CM. New treatment strategies for systemic vasculitis: the role of intravenous immune globulin therapy. Clin Exp Immunol 1996; 104 (Suppl. 01) 77-82
271 Lockwood CM, Thiru S, Stewart S. , et al. Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. QJM 1996; 89 (12) 903-912
272 Jayne DR, Rasmussen N. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc 1997; 72 (08) 737-747
273 Schmitt WH, Hagen EC, Neumann I, Nowack R, Flores-Suárez LF, van der Woude FJ. ; European Vasculitis Study Group. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 2004; 65 (04) 1440-1448
274 Sakai R, Kondo T, Kurasawa T. , et al. Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review. Clin Rheumatol 2017; 36 (10) 2383-2392
275 Imai H, Hotta O, Yoshimura M. , et al. Deoxyspergualin, an immunosuppressant, in patients suffering from nephropathies with crescent formation: an open-label trial to evaluate safety and efficacy. Clin Exp Nephrol 2006; 10 (01) 40-54
276 Birck R, Warnatz K, Lorenz HM. , et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 2003; 14 (02) 440-447
277 Flossmann O, Jayne DR. Long-term treatment of relapsing Wegener's granulomatosis with 15-deoxyspergualin. Rheumatology (Oxford) 2010; 49 (03) 556-562
278 Papo T, Le Thi Huong D, Wiederkehr JL. , et al. Etoposide in Wegener's granulomatosis. Rheumatology (Oxford) 1999; 38 (05) 473-475
279 Koening CL, Hernández-Rodríguez J, Molloy ES, Clark TM, Hoffman GS. Limited utility of rapamycin in severe, refractory Wegener's granulomatosis. J Rheumatol 2009; 36 (01) 116-119
280 Lynch III JP, Raghu G. Major disease syndromes of unknown etiology. In: Baum G, Crapo J. , eds. Textbook of Pulmonary Disease, 6th ed. Boston, MA: Little, Brown and Company; 1998: 431-476